TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Metastatic Triple-Negative Breast Cancer.Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA, Translational Breast Cancer Research Consortium
(2020)
Clin Cancer Res 26: 2111-2123
MeSH Terms: Androgen Receptor Antagonists, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Class I Phosphatidylinositol 3-Kinases, Female, Humans, Imidazoles, Middle Aged, Neoplasm Metastasis, Nitriles, Oxazepines, Phenylthiohydantoin, Protein Kinase Inhibitors, Receptors, Androgen, Survival Rate, Triple Negative Breast NeoplasmsAdded March 30, 2020